HTB

Conference reports

Switch study shows F/TAF non-inferior to continuing abacavir/3TC

No transmissions from breastfeeding in Tanzania cohort from mothers with undetectable viral load

Screening HIV positive pregnant women for TB in South Africa increased detection by 10-fold

Earlier ART reduces infant mortality in South Africa but risk of death and loss to follow up still high

Dolutegravir use in pregnancy: results from small Belgian cohort

Reassuring French data using raltegravir during pregnancy

16th European AIDS Conference (EACS 2017)

D/C/F/TAF: no impact on bioavailability of when tablet split but TAF reduced when crushed

Dolutegravir linked to less sleep but not cardiovascular or other CNS side effects, or IRIS

Dolutegravir-based dual therapy as switch option in multiple studies

D/C/F/TAF: phase 3 naive results and splitting PI-based FDC tablets

ABX464 nudges viral reservoir but not time to viral rebound

Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin

Fostemsavir in highly treatment-experienced participants: 24-week phase 3 results

Updated European guidelines launched at EACS 2017

9th IAS Conference on HIV Science (IAS 2017)

Dual therapy with darunavir/r plus lamivudine as first-line ART

Dual therapy with dolutegravir plus lamivudine as first-line ART

Once-daily raltegravir: 96-week results from the ONCEMRK study

New IPERGAY analysis shows on-demand PrEP dosing works with less frequent sex

On-demand dosing for PrEP is highly effective in French expanded access programme

Psychological impact of PrEP: beyond efficacy and cost-effectiveness

Early ART and testing HIV negative with rapid HIV tests

Report from the IAS HIV Cure & Cancer Forum, 22–23 July 2017, Paris

9th IAS Conference on HIV Science (IAS 2017)

HIV pipeline drugs: IAS 2017 update

Darunavir/cobicistat/FTC/TAF: 24-week interim results from phase 3 switch study

Phase 3 results with bictegravir FDC: a new integrase inhibitor combined with FTC/TAF

Doravirine/3TC/TDF compared to efavirenz/FTC/TDF as first-line ART

Continued viral suppression with long-acting cabotegravir/rilpivirine injections: 96-week LATTE-2 results

Reduced-dose darunavir is safe and effective in switch study

MK-8591: further compelling early results for both treatment and prevention

Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study

Preliminary results on dolutegravir use in pregnancy are reassuring

Low dose efavirenz (EFV400) can be used during pregnancy

Stillbirth rate in HIV positive women in UK/Ireland is double that of the general population

Swaziland nearly halves HIV incidence in five years

Gay men with undetectable viral load do not transmit HIV: Opposites Attract study supports U=U

HIV remission news from IAS 2017

Publications launched at IAS 2017

9th International Workshop on HIV Paediatrics, 21–22 July 2017, Paris

Chewable raltegravir tablets can be crushed and dispersed in liquid for young children

Inconsistencies between real-world data from UK and Ireland and EU recommendations for new antiretrovirals in pregnancy

18th International Workshop on Clinical Pharmacology of Antiviral Therapy, 14-16 June 2017, Chicago

Dolutegravir pharmacokinetics in pregnancy

High rates of of undocumented efavirenz-related side effects in Uganda

11th INTEREST Workshop, 16-19 May 2017, Lilongwe, Malawi

Increased risk of ART failure after low-level viraemia in a large South African cohort

Option B+ Malawi

24th Conference on Retroviruses and Opportunistic Infections (CROI 2017), 13-16 February 2017, Seattle

Impressive HIV pipeline at CROI 2017

Paediatric HIV: CROI 2017

23rd Annual Conference of BHIVA, 4-7 April 2017, Liverpool

Drop in HIV incidence in gay men: frequent testing, early ART and PrEP

Prompt/early ART: Dean Street pilot project reports 75% uptake

Potential for phylogenetic analysis to show direction of HIV transmission

Community presentations: dental care, HIV awareness and access to formula milk

Initiatives for earlier HIV diagnosis: opt-out ER and home testing

No new HIV cases in 398 people using PrEP at Dean Street clinic

Other selections and webcasts

24th Conference on Retroviruses and Opportunistic Infections (CROI 2017), 13-16 February 2017, Seattle

Dose reduction potential of nanoparticle ARV formulations confirmed in humans

VRC01 in HIV-exposed newborns: first results support monthly injections for those at risk through breastfeeding

Raltegravir pharmacokinetic targets met in high-risk HIV-exposed infants

Tenofovir alafenamide exposure is modestly higher in children than adults

Post navigation